ALSF Childhood Cancer Research Grants
With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,500 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
Project Title | Institution / Principal Investigator(s) | Grant Type | Year | State |
---|---|---|---|---|
Astatine-211 Meta-Astatobenzylguanidine ([211At]MABG) Targeted Radiotherapy for Disseminated Neuroblastoma | Children’s Hospital of Philadelphia / John Maris, MD | Reach Grants | 2016 | Pennsylvania |
Targeting PLK1 as a Common Mechanism in Ph-like ALL | University of Texas M.D. Anderson Cancer Center / Joya Chandra, PhD | Reach Grants | 2016 | Texas |
A Novel Target for Neuroblastoma Treatment | Beckman Research Institute of City of Hope / Linda Malkas, Ph.D. | Reach Grants | 2014 | California |
Circumventing Pediatric Solid Tumor Microenvironment Resistance by Combinatorial CAR NK and Immunomodulating Therapy | New York Medical College / Mitchell Cairo, MD | Reach Grants | 2023 | New York |
Feasibility Study of Dual Inhibition of MDM2 and Tubulin in Treatment of AML | Emory University / Muxiang Zhou, MD | Reach Grants | 2023 | Georgia |
Dual PTK7/GD2 Gamma Delta CAR T Cell Therapy for Neuroblastoma | Emory University / Kelly Goldsmith, MD & H. Trent Spencer, PhD & Chris B. Doering, PhD | Reach Grants | 2021 | Georgia |
Targeting a Novel Epigenetic Signature in Diffuse Intrinsic Pontine Gliomas | New York University School of Medicine / Danny Reinberg, PhD | Reach Grants | 2019 | New York |
Therapeutic Reactivation of p53 to Overcome Apoptotic Resistance in Pediatric Leukemia | Dana-Farber Cancer Institute / Loren Walensky, MD, PhD & Kimberly Stegmaier, MD | Reach Grants | 2015 | Massachusetts |
Stroma Biology Identifies Heparin as a Differentiating Agent in Neuroblastoma | Duke University Medical Center / Gerard Blobe, MD, PhD | Reach Grants | 2013 | North Carolina |
Neural Stem Cell-Mediated Drug Delivery for Targeted Treatment of Medulloblastoma | Beckman Research Institute of City of Hope / Margarita Gutova, MD | Reach Grants | 2013 | California |